
Orgenesis Investor Relations Material
Latest events

Q2 2023
Orgenesis

Q3 2024
13 Nov, 2024

Q2 2024
8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Orgenesis Inc
Access all reports
Orgenesis Inc. is engaged in the development, manufacture, and commercialization of cell and gene therapies (CGTs) for diabetes and other serious chronic medical conditions. We are currently focused on developing a stem cell therapy-based treatment for patients with type 1 diabetes that do not produce insulin. Our product, “MAVENcell,” could potentially become the first non-immunosuppressive pancreatic islet cell transplantation therapy and lead to a cure for every individual who has lost their insulin producing ability. Orgenesis Inc. was founded in 2008 and is based in Germantown, Maryland.
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
ORGS
Country
🇺🇸 United States